Lilly's Medicare GLP-1 push: what changed

Eli Lilly launched a campaign called 'A Life Covered' in 2024 to press for Medicare coverage of GLP-1 obesity drugs. At the centre of the campaign is a short film depicting a woman's decades-long struggle with weight, framing obesity as a lifelong condition that affects older adults as much as any other age group. The timing puts Lilly's advocacy directly in line with a longstanding gap in US federal drug coverage: Medicare Part D has excluded medications prescribed specifically for weight loss since the benefit was created in 2003^[1]. For beneficiaries who receive tirzepatide or semaglutide for their diabetes or cardiovascular risk, Part D pays. For those who receive the same molecules for obesity alone, it does not.

What the campaign is asking for

The core policy ask is straightforward: change the statute that prohibits Medicare from covering drugs 'when used for anorexia, weight loss, or weight gain.' That language sits in 42 USC 1396r-8(d)(2) and was incorporated into the Medicare Part D benefit when Congress passed the Medicare Modernization Act in 2003^[2]. Lilly markets its campaign as an older-adult issue: obesity rates among adults over 65 are substantial, but Part D beneficiaries cannot access Lilly's Zepbound (tirzepatide) or Novo Nordisk's Wegovy (semaglutide 2.4 mg) for weight management without paying full list price.

The short film, by Lilly's account, is designed to show policymakers that obesity is not a short-term condition a patient manages during working years and then resolves. The older adult framing is deliberate: older Americans are the primary Medicare population, and connecting their experience to the coverage gap makes the issue personal in a way that cost-effectiveness arguments do not.

What has already changed on Medicare access

Since Lilly launched the campaign, Medicare access to GLP-1s for weight management has shifted, though not through the statutory change the campaign calls for. As of July 1, 2026, Medicare beneficiaries can access covered GLP-1 weight-loss drugs at a $50 monthly copay through a temporary demonstration program called the Medicare GLP-1 Bridge^[3]. The Bridge uses Section 402 demonstration authority to sidestep the Part D exclusion without repealing it.

Covered drugs under the Bridge include Mounjaro, Ozempic, Rybelsus, Wegovy, and Zepbound (KwikPen formulation only). Drug manufacturers agreed to a negotiated net price of $245 per 30-day supply. Critically, the $50 copay does not count toward the Part D deductible or the annual out-of-pocket maximum, and the Bridge runs outside the normal Part D benefit structure entirely^[3]. The CMS originally scheduled the program to end December 2026, but extended it through December 2027 after the larger BALANCE Part D model was delayed indefinitely.

Why the statutory gap still matters

The Bridge is a demonstration, not a law. It can be ended, restricted, or allowed to expire by a future administration without Congressional action. The Treat and Reduce Obesity Act, which would create a permanent Part D benefit for obesity medications, has been introduced in multiple Congressional sessions and has not passed. A 2024 Health Affairs analysis estimated that full Medicare coverage of anti-obesity medications would cost between $3.1 billion and $6.1 billion annually, depending on uptake rates among newly eligible beneficiaries^[4].

That cost estimate matters for Lilly's campaign strategy. The A Life Covered film is not a policy brief; it is an effort to build public support for coverage by attaching a face to the gap. Industry advocacy campaigns of this kind aim to shift the political calculus so that legislators weigh constituent demand alongside the budget score. Whether the campaign achieves that shift is a question for the 119th Congress.

What this does not settle

The campaign is Lilly's, which means the framing serves Lilly's commercial interests. The company's Zepbound label covers chronic weight management and obstructive sleep apnea, as confirmed in the FDA prescribing information^[5]. Expanded Medicare coverage would increase the patient population that can afford tirzepatide for obesity. That does not make the coverage gap wrong to highlight, but it is context a reader should carry when evaluating the messaging.

Lilly is also not the only manufacturer with a stake. Novo Nordisk's semaglutide products (Wegovy, Ozempic) and its oral obesity drug are equally blocked by the same statute. The A Life Covered campaign has a Lilly face, but the underlying policy problem is class-wide.

The EMA took a different route: Mounjaro is approved in the EU for both type-2 diabetes and weight management under a single label, and access depends on national reimbursement decisions rather than a federal statutory exclusion^[6]. For a closer look at how coverage differs by country, see the tirzepatide regulation pages and the semaglutide overview.

Where things stand

Medicare beneficiaries who qualify can access GLP-1 weight-loss drugs through the Bridge program through at least December 2027 at a $50 copay. The underlying statutory exclusion for weight-loss medications has not changed. Lilly's campaign is one piece of industry pressure toward a permanent legislative fix; the outcome depends on whether Congress treats obesity coverage as a budget problem or a public-health obligation. That debate has not resolved, and the Bridge's expiration date keeps it live.